Clinical trials query results

From Health Canada


New search



Medical condition:
PLEURAL MESOTHELIOMA
Medical condition:
ADULT FEMALE,ADULT MALE
Drug name:
VOLRUSTOMIG (MEDI5752)
Protocol title:
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER, GLOBAL STUDY OF VOLRUSTOMIG (MEDI5752) IN COMBINATION WITH CARBOPLATIN PLUS PEMETREXED VERSUS PLATINUM PLUS PEMETREXED OR NIVOLUMAB PLUS IPILIMUMAB IN PARTICIPANTS WITH UNRESECTABLE PLEURAL MESOTHELIOMA (EVOLVE-MESO)
Sponsor name:
ASTRAZENECA CANADA INC
Date of no objection letter:
2023-08-17
Control number:
277409
Trial status:
ONGOING
Date study started:
2024-04-17
Date modified: